For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Exelixis, Inc.

USPTO Granted Patents = 177

% Expired Patents = 40.1

CIPO Patents = 13

EPO Patents = 69

Trademarks = 8

Forward Citations = 1,680

Loading Chart...

Loading Chart...

314 inventors (with patents filed for the assignee):

John M Nuss (27 out of 55 patents)

Wei Xu (26 out of 81 patents)

Yong Wang (25 out of 41 patents)

4. Lynne Canne Bannen (21 out of 27 patents)

5. James William Leahy (21 out of 25 patents)

6. Khalid Ali Shah (20 out of 38 patents)

7. Dana T Aftab (17 out of 18 patents)

8. Neel Kumar Anand (15 out of 39 patents)

9. Richard Martin (15 out of 54 patents)

10. Lori Friedman (15 out of 22 patents)

11. Peter Lamb (14 out of 14 patents)

12. Joerg Bussenius (14 out of 19 patents)

13. Kenneth D Rice (14 out of 23 patents)

14. Timothy Patrick Forsyth (14 out of 30 patents)

15. Helen Louise Francis-Lang (14 out of 15 patents)

Core Competencies:

Kinase Inhibitors

Quinoline Compounds

Adenosine Receptor Antagonists

PI3K Inhibitors

MEK Inhibitors

Cabozantinib

Cancer Treatment

Crystalline Forms

Drug Combinations

Liquid Dosage Forms

Pharmaceutical Compositions

Tumor Modulators

177 patents: Sort by Forward Citations

1. 12679809 - Crystalline forms and salt forms of a kinase inhibitor (2026-07-14),

2. 12673052 - Combinations for the treatment of cancer (2026-07-07),

3. 12503438 - Compounds for the treatment of kinase-dependent disorders (2025-12-23),

4. 12497367 - Processes for the preparation of a kinase inhibitor (2025-12-16),

5. 12486233 - Crystalline Solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2025-12-02),

6. 12371428 - Pyridone compounds and methods of use (2025-07-29),

7. 12275706 - Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer (2025-04-14),

8. 12264161 - Heterocyclic adenosine receptor antagonists (2025-04-01),

9. 12227481 - Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2025-02-18),

10. 12195475 - Compounds for the treatment of kinase-dependent disorders (2025-01-14),

11. 12128039 - Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds (2024-10-29),

12. 12084496 - Anti-ROR antibody constructs (2024-09-10),

13. 12017995 - Crystalline forms and salt forms of a kinase inhibitor (2024-06-25),

14. 12016854 - Liquid dosage forms to treat cancer (2024-06-25),

15. 11969419 - Method of treating cancer (2024-04-30),

Exelixis, Inc. is a biotechnology company focused on the discovery, development and commercialization of new medicines to improve the treatment of cancer and other serious diseases. With a robust pipeline of potential therapies, Exelixis is committed to advancing science to develop innovative treatments that can make a meaningful difference in patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

177 Patents

#9 in South San Francisco, CA

#499 in California

#2,280 in US

#4,697 in the World

South San Francisco, CA, United States of America

Exelixis, Inc.

Forward Citations = 1,680

314 inventors:

John M Nuss (27 out of 55 patents)

Wei Xu (26 out of 81 patents)

Yong Wang (25 out of 41 patents)

4. Lynne Canne Bannen (21 out of 27 patents)

5. James William Leahy (21 out of 25 patents)

Please report any incorrect information to [email protected]

Loading…